|
Age, years (SD)
|
71.4 (12.2)
|
74.4 (13.8)
|
0.138
|
|
Sex
|
0.421
|
|
Male
|
26 (63.4%)
|
112 (72.7%)
| |
|
Female
|
15 (36.6%)
|
42 (27.3%)
| |
|
BMI (SD)
|
22.2 (5.6)
|
22.3 (4.3)
|
0.788
|
|
Smoking
|
15 (36.6%)
|
63 (40.9%)
|
0.363
|
|
Comorbidities
| |
|
Diabetes
|
12 (29.5%)
|
45 (29.2%)
|
0.958
|
|
Malignancies
|
10 (24.4%)
|
23 (14.9%)
|
0.243
|
|
Renal insufficiency
|
6 (14.6%)
|
15 (9.7%)
|
0.211
|
|
Chronic liver diseases
|
3 (7.3%)
|
13 (8.4%)
|
1.000
|
|
Heart failure
|
3 (7.8%)
|
14 (9.1%)
|
0.767
|
|
CR-GNB culture sources
|
0.035
|
|
Respiratory specimens
|
39 (95.1%)
|
118 (76.6%)
| |
|
Urine
|
0
|
10 (6.5%)
| |
|
Blood
|
2 (4.9%)
|
9 (5.8%)
| |
|
Othersb
|
0
|
17 (11.0%)
| |
|
CR-GNB species
|
0.229
|
|
CRAB
|
34 (82.9)
|
107 (69.5%)
| |
|
CRE
|
6 (14.6%)
|
39 (25.3%)
| |
|
CRPA
|
1 (2.4%)
|
8 (5.2%)
| |
|
Laboratory results (Mean, SD)
| |
|
Leukocytes (× 109 per L)
|
11.5 (9.9)
|
13.7 (8.8)
|
0.183
|
|
CRP (mg/dL)
|
10.5 (10.0)
|
9.8 (5.6)
|
0.555
|
|
Albumin level
|
2.8 (2.5–3.1)
|
2.7 (2.4–3.0)
|
0.217
|
|
Concomitant nephrotoxins
| |
|
Aminoglycoside
|
5 (12.2%)
|
17 (11.0%)
|
0.835
|
|
Vancomycin
|
8 (19.5%)
|
12 (7.8%)
|
0.028
|
|
Intravenous contrast agent
|
9 (22%)
|
30 (19.5%)
|
0.725
|
|
Disease severities
| |
|
APACHEII scores (median, IQ R)c
|
23 (18–31)
|
25 (20–30)
|
0.454
|
|
Respiratory failured
|
40 (97.6%)
|
135 (87.7%)
|
0.081
|
|
Septic shockd
|
22 (53.7)
|
39 (25.3%)
|
0.001
|
|
Colistin treatment
| |
|
Daily dose (MIU) (median, IQR)
|
8 (7.4–10)
|
8 (4–10)
|
0.036
|
|
Treatment duration (days) (median, IQR)
|
7 (4–11)
|
7 (4–12)
|
0.403
|
|
Accumulated dose (MIU) (median, IQR)
|
46.5 (30.5–87.2)
|
48 (24–80)
|
0.594
|
|
Inappropriate colistin dose
|
9 (22.0%)
|
14 (9.1%)
|
0.023
|
